GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Aztreonam/avibactam - EMBLAVEO

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Emblaveo

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

EMBLAVEO: source applicability and renal evidence limits

The <=50 boundary and the loading-to-maintenance transition are retained from the detailed dosing tables; no dose is extrapolated to CRRT.

Before applying: Reassess changing CrCl; retain metronidazole for cIAI.

Evidence for this qualification

Selected-source comparison; independent clinician adjudication pending.

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

EMBLAVEO: selected primary-label renal guidance and limits

This source only - not a merged recommendation

What matters first

Product: Adult IV EMBLAVEO for labeled complicated intra-abdominal infection with concurrent metronidazole; not aztreonam alone.

Renal action / finding
Use the adult loading/maintenance table below, not a component-only dose.
Evidence or dialysis limit
Hemodialysis: administer after the session; no CRRT regimen established here.
Monitoring / application
Reassess changing CrCl; retain metronidazole for cIAI.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Product / population
Adult IV EMBLAVEO for labeled complicated intra-abdominal infection with concurrent metronidazole; not aztreonam alone.
Renal measure
Cockcroft-Gault CrCl, mL/min; total combination grams (3:1 aztreonam:avibactam)
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Hemodialysis: administer after the session; no CRRT regimen established here.

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Sections 2.1 and 2.2, Tables 1 and 2

Limits that apply to these rows

Read the complete source-specific limitations above and below this table. No patient dose is calculated.

Source-specific renal instructions
CrCl (mL/min)Loading totalMaintenance totalInterval
>502.67 g2 gEvery 6 hours
>30 to <=502.67 g1 gEvery 6 hours
>15 to <=301.8 g0.9 gEvery 8 hours
<=15, including HD1.33 g0.9 gEvery 12 hours
Read the retained text before reformatting

All doses infuse over 3 hours. Give one loading dose, then maintenance at the next interval; intervals run start-to-start. The table uses total combination dose, not aztreonam alone. Administer after hemodialysis on dialysis days. Follow changing CrCl closely; concurrent metronidazole is required for the labeled cIAI regimen.

Source revision: Revision date not captured in selected review; retrieval date is not revision date. | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be1a6c99-d4b3-46d7-9e99-6e5f9fab556a

Scope: Selected sections checked against the identified source; not a complete monograph or independent clinician approval. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

EMBLAVEO: selected primary-label renal guidance and limits

Source retrieved 2026-11-07 - confirm current applicability

A regimen is reported in selected content

Read the source and its limits

EMBLAVEO: selected RX renal passage

Source retrieved 2026-11-07 - confirm current applicability

A regimen is reported in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

EMBLAVEO: selected primary-label renal guidance and limits

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Hemodialysis: administer after the session; no CRRT regimen established here.

Dialysis evidence: A regimen is reported in selected content

Adult IV EMBLAVEO for labeled complicated intra-abdominal infection with concurrent metronidazole; not aztreonam alone.

Renal method: Cockcroft-Gault CrCl, mL/min; total combination grams (3:1 aztreonam:avibactam)
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

EMBLAVEO: selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Hemodialysis: administer after the session; no CRRT regimen established here.

Dialysis evidence: A regimen is reported in selected content

Adult IV EMBLAVEO for labeled complicated intra-abdominal infection with concurrent metronidazole; not aztreonam alone.

Renal method: Cockcroft-Gault CrCl, mL/min; total combination grams (3:1 aztreonam:avibactam)
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

EMBLAVEO: source applicability and renal evidence limits

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

EMBLAVEO: source applicability and renal evidence limits

The <=50 boundary and the loading-to-maintenance transition are retained from the detailed dosing tables; no dose is extrapolated to CRRT.

How to use this: Reassess changing CrCl; retain metronidazole for cIAI.

EMBLAVEO: selected primary-label renal guidance and limitsEMBLAVEO: selected RX renal passage

Selected-source comparison; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source

EMBLAVEO: selected primary-label renal guidance and limits

Adult IV EMBLAVEO for labeled complicated intra-abdominal infection with concurrent metronidazole; not aztreonam alone.

Method: Cockcroft-Gault CrCl, mL/min; total combination grams (3:1 aztreonam:avibactam)

Read this complete source summary
Rxlist source

EMBLAVEO: selected RX renal passage

Adult IV EMBLAVEO for labeled complicated intra-abdominal infection with concurrent metronidazole; not aztreonam alone.

Method: Cockcroft-Gault CrCl, mL/min; total combination grams (3:1 aztreonam:avibactam)

Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeEMBLAVEO (aztreonam and avibactam) for injectionEMBLAVEO: selected primary-label renal guidance and limitsEMBLAVEO: selected RX renal passage
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be1a6c99-d4b3-46d7-9e99-6e5f9fab556a

Product and population scope

U.S. IV combination product for adults with complicated intra-abdominal infection and limited alternatives, used with metronidazole. Not single-agent aztreonam or ceftazidime/avibactam.

aztreonam-avibactam-emblaveo:scope · Source section: Selected U.S. label: product title, route, dosage form and indicationRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

EMBLAVEO (aztreonam and avibactam) for injection

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. prescribing information · Adults; IV fixed combination; doses below are TOTAL combination grams.

Renal method: Not specified in this summary.
Source date:
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Renal-adjusted loading and maintenance doses

Use Cockcroft-Gault CrCl in mL/min. All infusions last 3 hours.

  • >50: load 2.67 g, then 2 g every 6 hours.
  • >30 to 50: load 2.67 g, then 1 g every 6 hours.
  • >15 to 30: load 1.8 g, then 0.9 g every 8 hours.
  • <=15, including HD: load 1.33 g, then 0.9 g every 12 hours.

aztreonam-avibactam-emblaveo:dm-be1a6c99-d4b3-46d7-9e99-6e5f9fab556a-1 · Source locator: 2.1-2.2, Tables 1-2

Timing and limits

Maintenance starts at the next dosing interval after the single load; intervals run from infusion start to infusion start. Give after HD on dialysis days and monitor changing renal function closely. The labeled course is 5-14 days with concurrent metronidazole. Approval rests on limited clinical safety/efficacy data.

aztreonam-avibactam-emblaveo:dm-be1a6c99-d4b3-46d7-9e99-6e5f9fab556a-2 · Source locator: 1.1; 2.1-2.2; 8.6

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be1a6c99-d4b3-46d7-9e99-6e5f9fab556a
Retrieved
2026-09-05
Exact label title
EMBLAVEO (aztreonam and avibactam) for injection
DailyMed Set ID
be1a6c99-d4b3-46d7-9e99-6e5f9fab556a
Labeler
AbbVie Inc.
DailyMed page updated
2026-06-24
FDA application
NDA marketing category; initial U.S. approval 2025
U.S. product identity basis
Exact named product and route appear in the selected U.S. prescription label; current retail availability was not independently assessed.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
4d82048cba4b5ec3004bac42ca815258da44cfbcc9313ded54b0220e509cc506
Official

EMBLAVEO: selected primary-label renal guidance and limits

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Adult IV EMBLAVEO for labeled complicated intra-abdominal infection with concurrent metronidazole; not aztreonam alone.

Renal method: Cockcroft-Gault CrCl, mL/min; total combination grams (3:1 aztreonam:avibactam)
Source date: Revision date not captured in selected review; retrieval date is not revision date.
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Hemodialysis: administer after the session; no CRRT regimen established here.

Dialysis evidence: A regimen is reported in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Sections 2.1 and 2.2, Tables 1 and 2

Limits that apply to these rows

Read the complete source-specific limitations above and below this table. No patient dose is calculated.

Source-specific renal instructions
CrCl (mL/min)Loading totalMaintenance totalInterval
>502.67 g2 gEvery 6 hours
>30 to <=502.67 g1 gEvery 6 hours
>15 to <=301.8 g0.9 gEvery 8 hours
<=15, including HD1.33 g0.9 gEvery 12 hours
Read the retained text before reformatting

All doses infuse over 3 hours. Give one loading dose, then maintenance at the next interval; intervals run start-to-start. The table uses total combination dose, not aztreonam alone. Administer after hemodialysis on dialysis days. Follow changing CrCl closely; concurrent metronidazole is required for the labeled cIAI regimen.

RDM72-aztreonam-avibactam-emblaveo-label-1 · Source locator: Sections 2.1 and 2.2, Tables 1 and 2

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be1a6c99-d4b3-46d7-9e99-6e5f9fab556a
Retrieved
2026-11-07
Renal-function method
Cockcroft-Gault CrCl, mL/min; total combination grams (3:1 aztreonam:avibactam)
Source date/version
Revision date not captured in selected review; retrieval date is not revision date.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
735a6634bafc3184035b305f2ee02082af591c0d4d467768a039589fbf056dcf
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

EMBLAVEO: selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / label mirror · Adult IV EMBLAVEO for labeled complicated intra-abdominal infection with concurrent metronidazole; not aztreonam alone.

Renal method: Cockcroft-Gault CrCl, mL/min; total combination grams (3:1 aztreonam:avibactam)
Source date: Revision date not established in reviewed mirror passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Hemodialysis: administer after the session; no CRRT regimen established here.

Dialysis evidence: A regimen is reported in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Sections 2.1 and 2.2, Tables 1 and 2

The RX dosing section supplies CrCl-based loading and maintenance doses with three-hour infusions and post-hemodialysis timing. It uses Cockcroft-Gault and total combination dose; the mirror is not an independent regimen.

RDM72-aztreonam-avibactam-emblaveo-rx-1 · Source locator: Sections 2.1 and 2.2, Tables 1 and 2

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/emblaveo-drug/
Retrieved
2026-11-07
Renal-function method
Cockcroft-Gault CrCl, mL/min; total combination grams (3:1 aztreonam:avibactam)
Source date/version
Revision date not established in reviewed mirror passage.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
3104cd217c874406ce408577993cedc61873fb32d1ec912b5304e26f13e1a7b8

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be1a6c99-d4b3-46d7-9e99-6e5f9fab556a
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
official new drug
Local text SHA-256
1d76837c4fcc486ad931096684497fb48f0e45bc2ced635712eb7eae714cb76c
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top